Mineralocorticoid receptor
Homo sapiens
State in the Current Structure
| Assembly | Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Associated Components | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|
| 1 | Protein monomer Monomer Protein × 1 PDB declaration: monomeric(1) Consistent with protein copy count | Chain A; UniProt 712–984 | Fragment:LIGAND-BINDING DOMAIN, UNP residues 712-984 Mutation:C808S, S810L | SNL SPIRONOLACTONE × 1 | X-RAY DIFFRACTION X-ray crystallization conditions:VAPOR DIFFUSION, SITTING DROP;pH 7;293 K;0.1M HEPES pH 7.0, 1.26M Lithium sulfate, 6% PEG MME 2000, VAPOR DIFFUSION, SITTING DROP, temperature 293K | Resolution 2.11 Å R-free 0.246 |
Other States of the Same Protein in the Database
Each row is a biological assembly of the same UniProt protein in another PDB entry. The “Difference from current entry” column identifies evidence-level differences; no tag means the currently parsed fields agree.
| Other PDB | Difference from Current Entry 3VHU | Assembly / Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Non-polymers | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|---|
| 1Y9R Crystal structure of the human mineralocorticoid receptor ligand-binding domain bound to deoxycorticosterone and harboring the S810L mutation responsible for a severe form of hypertension Deposited 2004-12-16 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
731–984(254 aa)
Fragment:LIGAND-BINDING DOMAIN
|
Mutation:S810L, C910A | 1CA DESOXYCORTICOSTERONE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7;297 K;PEG 4000, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 297K
|
Resolution 1.96 Å R-free 0.267 |
| 1Y9R Crystal structure of the human mineralocorticoid receptor ligand-binding domain bound to deoxycorticosterone and harboring the S810L mutation responsible for a severe form of hypertension Deposited 2004-12-16 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain B
731–984(254 aa)
Fragment:LIGAND-BINDING DOMAIN
|
Mutation:S810L, C910A | 1CA DESOXYCORTICOSTERONE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7;297 K;PEG 4000, pH 7.0, VAPOR DIFFUSION, HANGING DROP, temperature 297K
|
Resolution 1.96 Å R-free 0.267 |
| 1YA3 Crystal structure of the human mineralocorticoid receptor ligand-binding domain bound to progesterone and harboring the S810L mutation responsible for a severe form of hypertension Deposited 2004-12-17 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
731–984(254 aa)
Fragment:LIGAND-BINDING DOMAIN
|
Mutation:S810L, C910A | STR PROGESTERONE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.8;297 K;PEG 4000, pH 6.8, VAPOR DIFFUSION, HANGING DROP, temperature 297K
|
Resolution 2.34 Å R-free 0.284 |
| 1YA3 Crystal structure of the human mineralocorticoid receptor ligand-binding domain bound to progesterone and harboring the S810L mutation responsible for a severe form of hypertension Deposited 2004-12-17 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain B
731–984(254 aa)
Fragment:LIGAND-BINDING DOMAIN
|
Mutation:S810L, C910A | STR PROGESTERONE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.8;297 K;PEG 4000, pH 6.8, VAPOR DIFFUSION, HANGING DROP, temperature 297K
|
Resolution 2.34 Å R-free 0.284 |
| 1YA3 Crystal structure of the human mineralocorticoid receptor ligand-binding domain bound to progesterone and harboring the S810L mutation responsible for a severe form of hypertension Deposited 2004-12-17 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain C
731–984(254 aa)
Fragment:LIGAND-BINDING DOMAIN
|
Mutation:S810L, C910A | STR PROGESTERONE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.8;297 K;PEG 4000, pH 6.8, VAPOR DIFFUSION, HANGING DROP, temperature 297K
|
Resolution 2.34 Å R-free 0.284 |
| 2A3I Structural and Biochemical Mechanisms for the Specificity of Hormone Binding and Coactivator Assembly by Mineralocorticoid Receptor Deposited 2005-06-24 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain A
732–984(253 aa)
Fragment:Mineralocoricoid receptor
|
Mutation:C808S | C0R CORTICOSTERONE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION;pH 7.9;293 K;PEG mme5K, Sodium Acetate, 1-6 Hexanediol, pH 7.9, VAPOR DIFFUSION, temperature 293K
|
Resolution 1.95 Å R-free 0.253 |
| 2AA2 Mineralocorticoid Receptor with Bound Aldosterone Deposited 2005-07-13 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
712–984(273 aa)
|
Mutation:C808S | BOG octyl beta-D-glucopyranoside × 1 SO4 SULFATE ION × 1 AS4 ALDOSTERONE × 1 GOL GLYCEROL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;0.1M Hepes pH7.5, 0.9M Lithium Sulfate, 2% PEG2KMME, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.95 Å R-free 0.235 |
| 2AA5 Mineralocorticoid Receptor with Bound Progesterone Deposited 2005-07-13 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
712–984(273 aa)
Fragment:Ligand Binding Domain
|
Mutation:C808S | STR PROGESTERONE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;0.1m Hepes pH7.5, 0.9M Li2SO4, 2% PEG 2KMME, vapor diffusion, hanging drop, temperature 298K
|
Resolution 2.20 Å R-free 0.264 |
| 2AA5 Mineralocorticoid Receptor with Bound Progesterone Deposited 2005-07-13 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain B
712–984(273 aa)
Fragment:Ligand Binding Domain
|
Mutation:C808S | STR PROGESTERONE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;0.1m Hepes pH7.5, 0.9M Li2SO4, 2% PEG 2KMME, vapor diffusion, hanging drop, temperature 298K
|
Resolution 2.20 Å R-free 0.264 |
| 2AA6 Mineralocorticoid Receptor S810L Mutant with Bound Progesterone Deposited 2005-07-13 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
712–984(273 aa)
Fragment:Ligand Binding Domain
|
Mutation:C808S, S810L | STR PROGESTERONE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;0.1m Hepes pH7.5, 0.9M Li2SO4, 2% PEG 2KMME, vapor diffusion, hanging drop, temperature 298K
|
Resolution 1.95 Å R-free 0.225 |
| 2AA6 Mineralocorticoid Receptor S810L Mutant with Bound Progesterone Deposited 2005-07-13 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain B
712–984(273 aa)
Fragment:Ligand Binding Domain
|
Mutation:C808S, S810L | STR PROGESTERONE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;0.1m Hepes pH7.5, 0.9M Li2SO4, 2% PEG 2KMME, vapor diffusion, hanging drop, temperature 298K
|
Resolution 1.95 Å R-free 0.225 |
| 2AA7 Mineralocorticoid Receptor with Bound Deoxycorticosterone Deposited 2005-07-13 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
712–984(273 aa)
Fragment:Ligand Binding Domain
|
Mutation:C808S | SO4 SULFATE ION × 1 1CA DESOXYCORTICOSTERONE × 1 GOL GLYCEROL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;0.1m Hepes pH7.5, 0.9M Li2SO4, 2% PEG 2KMME, vapor diffusion, hanging drop, temperature 298K
|
Resolution 2.20 Å R-free 0.264 |
| 2AAX Mineralocorticoid Receptor Double Mutant with Bound Cortisone Deposited 2005-07-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric |
Chain A
712–984(273 aa)
Fragment:Ligand Binding Domain
Chain B
712–984(273 aa)
Fragment:Ligand Binding Domain
|
Mutation:C808S, S810L Mutation:C808S, S810L | SO4 SULFATE ION × 1 PDN 17,21-DIHYDROXYPREGNA-1,4-DIENE-3,11,20-TRIONE × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;0.1m Hepes pH7.5, 0.9M Li2SO4, 2% PEG 2KMME, vapor diffusion, hanging drop, temperature 298K
|
Resolution 1.75 Å R-free 0.212 |
| 2AB2 Mineralocorticoid Receptor Double Mutant with Bound Spironolactone Deposited 2005-07-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric |
Chain A
712–984(273 aa)
Fragment:MR Ligand Binding Domain
Chain B
712–984(273 aa)
Fragment:MR Ligand Binding Domain
|
Mutation:C808S, S810L Mutation:C808S, S810L | SNL SPIRONOLACTONE × 2 SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;0.1m Hepes pH7.5, 0.9M Li2SO4, 2% PEG 2KMME, vapor diffusion, hanging drop, temperature 298K
|
Resolution 1.85 Å R-free 0.218 |
| 2ABI Crystal structure of the human mineralocorticoid receptor ligand-binding domain bound to deoxycorticosterone Deposited 2005-07-15 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
731–984(254 aa)
Fragment:LIGAND-BINDING DOMAIN
|
Mutation:C910A | 1CA DESOXYCORTICOSTERONE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.1;297 K;PEG4000, HEPES, pH 7.1, VAPOR DIFFUSION, HANGING DROP, temperature 297K
|
Resolution 2.33 Å R-free 0.264 |
| 2ABI Crystal structure of the human mineralocorticoid receptor ligand-binding domain bound to deoxycorticosterone Deposited 2005-07-15 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain B
731–984(254 aa)
Fragment:LIGAND-BINDING DOMAIN
|
Mutation:C910A | 1CA DESOXYCORTICOSTERONE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.1;297 K;PEG4000, HEPES, pH 7.1, VAPOR DIFFUSION, HANGING DROP, temperature 297K
|
Resolution 2.33 Å R-free 0.264 |
| 2ABI Crystal structure of the human mineralocorticoid receptor ligand-binding domain bound to deoxycorticosterone Deposited 2005-07-15 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain C
731–984(254 aa)
Fragment:LIGAND-BINDING DOMAIN
|
Mutation:C910A | 1CA DESOXYCORTICOSTERONE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.1;297 K;PEG4000, HEPES, pH 7.1, VAPOR DIFFUSION, HANGING DROP, temperature 297K
|
Resolution 2.33 Å R-free 0.264 |
| 2OAX Crystal structure of the S810L mutant mineralocorticoid receptor associated with SC9420 Deposited 2006-12-18 | Different construct Different mutation/modification Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
731–984(254 aa)
Fragment:LIGAND-BINDING DOMAIN
|
Mutation:S810L,C910A | SNL SPIRONOLACTONE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.8;297 K;HEPES 100 mM, pH 6.8, 230 mM NaCl, 25% PEG4000, VAPOR DIFFUSION, HANGING DROP, temperature 297K
|
Resolution 2.29 Å R-free 0.263 |
| 2OAX Crystal structure of the S810L mutant mineralocorticoid receptor associated with SC9420 Deposited 2006-12-18 | Different construct Different mutation/modification Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain B
731–984(254 aa)
Fragment:LIGAND-BINDING DOMAIN
|
Mutation:S810L,C910A | SNL SPIRONOLACTONE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.8;297 K;HEPES 100 mM, pH 6.8, 230 mM NaCl, 25% PEG4000, VAPOR DIFFUSION, HANGING DROP, temperature 297K
|
Resolution 2.29 Å R-free 0.263 |
| 2OAX Crystal structure of the S810L mutant mineralocorticoid receptor associated with SC9420 Deposited 2006-12-18 | Different construct Different mutation/modification Different experimental conditions Different structure-quality metrics | Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain C
731–984(254 aa)
Fragment:LIGAND-BINDING DOMAIN
|
Mutation:S810L,C910A | SNL SPIRONOLACTONE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.8;297 K;HEPES 100 mM, pH 6.8, 230 mM NaCl, 25% PEG4000, VAPOR DIFFUSION, HANGING DROP, temperature 297K
|
Resolution 2.29 Å R-free 0.263 |
| 2OAX Crystal structure of the S810L mutant mineralocorticoid receptor associated with SC9420 Deposited 2006-12-18 | Different construct Different mutation/modification Different experimental conditions Different structure-quality metrics | Assembly 4 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain D
731–984(254 aa)
Fragment:LIGAND-BINDING DOMAIN
|
Mutation:S810L,C910A | SNL SPIRONOLACTONE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.8;297 K;HEPES 100 mM, pH 6.8, 230 mM NaCl, 25% PEG4000, VAPOR DIFFUSION, HANGING DROP, temperature 297K
|
Resolution 2.29 Å R-free 0.263 |
| 2OAX Crystal structure of the S810L mutant mineralocorticoid receptor associated with SC9420 Deposited 2006-12-18 | Different construct Different mutation/modification Different experimental conditions Different structure-quality metrics | Assembly 5 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain E
731–984(254 aa)
Fragment:LIGAND-BINDING DOMAIN
|
Mutation:S810L,C910A | SNL SPIRONOLACTONE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.8;297 K;HEPES 100 mM, pH 6.8, 230 mM NaCl, 25% PEG4000, VAPOR DIFFUSION, HANGING DROP, temperature 297K
|
Resolution 2.29 Å R-free 0.263 |
| 2OAX Crystal structure of the S810L mutant mineralocorticoid receptor associated with SC9420 Deposited 2006-12-18 | Different construct Different mutation/modification Different experimental conditions Different structure-quality metrics | Assembly 6 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain F
731–984(254 aa)
Fragment:LIGAND-BINDING DOMAIN
|
Mutation:S810L,C910A | SNL SPIRONOLACTONE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.8;297 K;HEPES 100 mM, pH 6.8, 230 mM NaCl, 25% PEG4000, VAPOR DIFFUSION, HANGING DROP, temperature 297K
|
Resolution 2.29 Å R-free 0.263 |
| 3VHV Mineralocorticoid receptor ligand-binding domain with non-steroidal antagonist Deposited 2011-09-07 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
727–984(258 aa)
Fragment:LIGAND-BINDING DOMAIN, UNP residues 727-984
|
Mutation:C808S, S810L, A976V | LD1 6-[(7S)-7-phenyl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazin-6-yl]-2H-1,4-benzoxazin-3(4H)-one × 1 LD2 6-[(1E)-2-phenyl-N-(3-sulfanyl-4H-1,2,4-triazol-4-yl)ethanimidoyl]-2H-1,4-benzoxazin-3(4H)-one × 1 EDO 1,2-ETHANEDIOL × 2 K POTASSIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.4;293 K;0.1M HEPES pH 7.4, 0.88M potassium/sodium tartrate, 5% ethylene glycol, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.35 Å R-free 0.167 |
| 3WFF Mineralocorticoid receptor ligand-binding domain with compound 2b Deposited 2013-07-19 | Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
712–984(273 aa)
Fragment:LIGAND-BINDING DOMAIN, UNP residues 712-984
|
Mutation:C808S, S810L, A976V | WFF 6-[4-(2,4-difluorophenyl)-5-oxo-2,5-dihydrofuran-3-yl]-2H-1,4-benzoxazin-3(4H)-one × 1 PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.2;293 K;0.04M potassium dihydrogen phosphate, 16% PEG 8000, 20% glycerol, pH 7.2, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.05 Å R-free 0.216 |
| 3WFG Mineralocorticoid receptor ligand-binding domain with compuond 2e Deposited 2013-07-19 | Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
712–984(273 aa)
Fragment:LIGAND-BINDING DOMAIN, UNP residues 712-984
|
Mutation:C808S, S810L, A976V | WFG 6-[(2S)-4-(4-fluorophenyl)-2-methyl-5-oxo-2,5-dihydrofuran-3-yl]-2H-1,4-benzoxazin-3(4H)-one × 1 EDO 1,2-ETHANEDIOL × 13 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.8;293 K;0.1M Tris, 23% ethanol, pH 7.8, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.40 Å R-free 0.179 |
| 4PF3 Mineralocorticoid receptor ligand-binding domain with compuond 37a Deposited 2014-04-28 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
716–988(273 aa)
Fragment:UNP residues 716-988
|
Mutation:C808S, S810L, A976V | HFN 6-[1-(2,2-difluoro-3-hydroxypropyl)-5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]-2H-1,4-benzoxazin-3(4H)-one × 1 EDO 1,2-ETHANEDIOL × 8 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 8;293 K;0.1M Tris pH 8.0, 23% ethanol
|
Resolution 1.10 Å R-free 0.177 |
| 4TNT Structure of the human mineralocorticoid receptor in complex with DNA Deposited 2014-06-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein–DNA Homooligomer;Protein × 2 PDB declaration: tetrameric |
Chain A
593–671(79 aa)
Chain B
593–671(79 aa)
|
Not recorded | ZN ZINC ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;298 K;0.2 M sodium malonate, 12 % PEG 3350
|
Resolution 2.39 Å R-free 0.258 |
| 4UDA MR in complex with dexamethasone Deposited 2014-12-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain A
735–984(250 aa)
Fragment:LIGAND BINDING DOMAIN, RESIDUES 735-984
|
Mutation:YES | GOL GLYCEROL × 1 DEX DEXAMETHASONE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.5;30% PEG4000, 0.1M NACL, 0.2M PIPES PH 7.5
|
Resolution 2.03 Å R-free 0.240 |
| 4UDB MR in complex with desisobutyrylciclesonide Deposited 2014-12-09 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain A
735–984(250 aa)
Fragment:LIGAND BINDING DOMAIN, RESIDUES 735-984
|
Mutation:YES | DMS DIMETHYL SULFOXIDE × 1 GOL GLYCEROL × 1 SO4 SULFATE ION × 1 CV7 DESISOBUYTYRYL CICLESONIDE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8.5;18% PEG4K, 0.14M LISO4, 85MM TRIS PH 8.5, 15% GLYCEROL
|
Resolution 2.36 Å R-free 0.218 |
| 5HCV Identification of Spirooxindole and Dibenzoxazepine Motifs as Potent Mineralocorticoid Receptor Antagonists Deposited 2016-01-04 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
732–984(253 aa)
Fragment:ligand-binding domain (UNP residues 732-984)
|
Mutation:C808S | 60R 6-[(~{E})-(3-fluoranyl-6~{H}-benzo[c][1]benzoxepin-11-ylidene)methyl]-4~{H}-1,4-benzoxazin-3-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 8;294 K;1uL of protein complex at 8-10mg protein/ml is mixed with an equal volume of reservoir solution composed of 100mM Tris-HCl pH=8.0, 200mM NaCl, 5% (v/v) glycerol, 16%(w/v) PEG3350
|
Resolution 2.50 Å R-free 0.256 |
| 5HCV Identification of Spirooxindole and Dibenzoxazepine Motifs as Potent Mineralocorticoid Receptor Antagonists Deposited 2016-01-04 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain B
732–984(253 aa)
Fragment:ligand-binding domain (UNP residues 732-984)
|
Mutation:C808S | 60R 6-[(~{E})-(3-fluoranyl-6~{H}-benzo[c][1]benzoxepin-11-ylidene)methyl]-4~{H}-1,4-benzoxazin-3-one × 1 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 8;294 K;1uL of protein complex at 8-10mg protein/ml is mixed with an equal volume of reservoir solution composed of 100mM Tris-HCl pH=8.0, 200mM NaCl, 5% (v/v) glycerol, 16%(w/v) PEG3350
|
Resolution 2.50 Å R-free 0.256 |
| 5HCV Identification of Spirooxindole and Dibenzoxazepine Motifs as Potent Mineralocorticoid Receptor Antagonists Deposited 2016-01-04 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain C
732–984(253 aa)
Fragment:ligand-binding domain (UNP residues 732-984)
|
Mutation:C808S | 60R 6-[(~{E})-(3-fluoranyl-6~{H}-benzo[c][1]benzoxepin-11-ylidene)methyl]-4~{H}-1,4-benzoxazin-3-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 8;294 K;1uL of protein complex at 8-10mg protein/ml is mixed with an equal volume of reservoir solution composed of 100mM Tris-HCl pH=8.0, 200mM NaCl, 5% (v/v) glycerol, 16%(w/v) PEG3350
|
Resolution 2.50 Å R-free 0.256 |
| 5L7E MCR IN COMPLEX WITH ligand Deposited 2016-06-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain A
735–984(250 aa)
|
Not recorded | NHE 2-[N-CYCLOHEXYLAMINO]ETHANE SULFONIC ACID × 1 MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 1 SO4 SULFATE ION × 1 EDO 1,2-ETHANEDIOL × 2 6Q0 ~{N}-[[4-(3,5-dimethyl-1,2-oxazol-4-yl)phenyl]methyl]benzenesulfonamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION;293 K;1.6 M AMS 0.1 M CHES pH 9.5 15% EG 10% Morpheus F12
|
Resolution 1.86 Å R-free 0.197 |
| 5L7G MCR IN COMPLEX WITH ligand Deposited 2016-06-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain A
739–988(250 aa)
|
Not recorded | EDO 1,2-ETHANEDIOL × 1 6QE ~{N}-[[4-[5-[[2,3-bis(fluoranyl)phenoxy]methyl]-3-methyl-1,2-oxazol-4-yl]phenyl]methyl]-1-methyl-cyclopropane-1-sulfonamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION;293 K;0.9 M AMS 0.1 M CHES pH 9.5 +10% Morpheus C9
|
Resolution 2.01 Å R-free 0.243 |
| 5L7H MCR IN COMPLEX WITH ligand Deposited 2016-06-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain A
735–984(250 aa)
|
Not recorded | 6QG 3-methyl-5,8-dioxa-17lambda-thia-4,18-diazatetracyclo[18.2.2.1,.0]pentacosa-1(22),2(6),3,9,11,13(25),20,23-octaene-17,17-dione × 1 NHE 2-[N-CYCLOHEXYLAMINO]ETHANE SULFONIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION;293 K;0.9 M AMS 0.1 M CHES pH 9.5 +10% Morpheus G5
|
Resolution 1.84 Å R-free 0.224 |
| 5MWP The structure of MR in complex with AZD9977. Deposited 2017-01-19 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
735–984(250 aa)
|
Mutation:C808S, C910S | ECV 2-[(3~{S})-7-fluoranyl-4-[(3-oxidanylidene-4~{H}-1,4-benzoxazin-6-yl)carbonyl]-2,3-dihydro-1,4-benzoxazin-3-yl]-~{N}-methyl-ethanamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;0.9 M (NH4)2SO4, 0.1 M CHES pH 9.5, and 10% (v/v) of conditions E5 from the Morpheus Screen (Molecular Dimensions).
|
Resolution 1.82 Å R-free 0.242 |
| 5MWY The structure of MR in complex with eplerenone. Deposited 2017-01-20 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
735–984(250 aa)
|
Not recorded | YNU eplerenone × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;0.9 M (NH4)2SO4, 0.1 M CHES pH 9.5, and 10% (v/v) of conditions G6 from the Morpheus Screen (Molecular Dimensions)
|
Resolution 1.75 Å R-free 0.245 |
| 6GEV Mineralocorticoid receptor in complex with (s)-13 Deposited 2018-04-27 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain A
735–984(250 aa)
|
Not recorded | GOL GLYCEROL × 3 EWN 6-[[(3~{S})-7-fluoranyl-3-(2-methylpropyl)-2,3-dihydro-1,4-benzoxazin-4-yl]carbonyl]-4~{H}-1,4-benzoxazin-3-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;0.9 M (NH4)2SO4, 3.5% 1,4-butanediol, 0.1 M CHES pH 9.5
|
Resolution 1.54 Å R-free 0.190 |
| 6GG8 Mineralocorticoid receptor in complex with (s)-13 Deposited 2018-05-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain A
735–984(250 aa)
|
Not recorded | MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 1 EY8 [(3~{R})-7-fluoranyl-4-[(3-oxidanylidene-4~{H}-1,4-benzoxazin-6-yl)carbonyl]-2,3-dihydro-1,4-benzoxazin-3-yl]methanesulfonamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;0.9M (NH4)2SO4, 0.1 M CHES pH9.5, 10% (v/v) of condition C8 of the Morpheus Screen (Molecular Dimension)
|
Resolution 1.80 Å R-free 0.228 |
| 6GGG Mineralocorticoid receptor in complex with (s)-13 Deposited 2018-05-03 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain A
735–984(250 aa)
|
Not recorded | CL CHLORIDE ION × 1 EYN 2-[(3~{S})-7-fluoranyl-6-(2-methylpropyl)-4-[(3-oxidanylidene-4~{H}-1,4-benzoxazin-6-yl)carbonyl]-2,3-dihydro-1,4-benzoxazin-3-yl]-~{N}-methyl-ethanamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;Condition C2 of the morpheus screen (Molecular Dimension).
|
Resolution 1.71 Å R-free 0.192 |
| 6L88 Crystal structure of mineralocorticoid receptor ligand binding domain in complex with esaxerenone Deposited 2019-11-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric |
Chain A
735–984(250 aa)
Chain D
735–984(250 aa)
|
Mutation:C808S,C910S Mutation:C808S,C910S | E6R 1-(2-hydroxyethyl)-4-methyl-N-(4-methylsulfonylphenyl)-5-[2-(trifluoromethyl)phenyl]pyrrole-3-carboxamide × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 8;293 K;2.0-2.5 M sodium nitrate, 0.1 M Tris-HCl pH 8.0
|
Resolution 3.00 Å R-free 0.307 |
| 6L88 Crystal structure of mineralocorticoid receptor ligand binding domain in complex with esaxerenone Deposited 2019-11-05 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric |
Chain B
735–984(250 aa)
Chain C
735–984(250 aa)
|
Mutation:C808S,C910S Mutation:C808S,C910S | E6R 1-(2-hydroxyethyl)-4-methyl-N-(4-methylsulfonylphenyl)-5-[2-(trifluoromethyl)phenyl]pyrrole-3-carboxamide × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 8;293 K;2.0-2.5 M sodium nitrate, 0.1 M Tris-HCl pH 8.0
|
Resolution 3.00 Å R-free 0.307 |
| 9GC7 Mineralocorticoid receptor in complex with acylurea antagonists. Deposited 2024-08-01 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
735–984(250 aa)
|
Mutation:C808S, S810L, C910S | MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 1 NHE 2-[N-CYCLOHEXYLAMINO]ETHANE SULFONIC ACID × 1 A1IJ6 (2S)-N-aminocarbonyl-2-[(4-cyano-6-cyclopropyl-cyclohexa-1,2,3,5-tetraen-1-yl)amino]propanamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293.15 K;0.9 M AMS 0.1 M CHES pH 9.5 +10% Morpheus G8
|
Resolution 1.46 Å R-free 0.210 |
29 other PDB entries and 44 assemblies. Open the comparison page and filter oligomeric states
View Construct and Data Evidence
| UniProt name | MCR_HUMAN |
| Isoform | — |
| PDB entities | 1 |
| Chains and sequence ranges | Author chain A; PDBConstruct 22–294; UniProt 712–984 |